Makoto Harada, Siyu Han, Mengya Shi, Jianhong Ge, Shixiang Yu, Jonathan Adam, Jerzy Adamski, Markus F Scheerer, Susanne Neschen, Martin Hrabe de Angelis, Rui Wang-Sattler
Combining a Sodium-Glucose-Cotransporter-2-inhibitor (SGLT2i) with metformin is recommended for managing hyperglycemia in patients with type 2 diabetes (T2D) who have cardio-renal complications. Our study aimed to investigate the metabolic effects of SGLT2i and metformin, both individually and synergistically. We treated leptin receptor-deficient (db/db) mice with these drugs for two weeks and conducted metabolite profiling, identifying 861 metabolites across kidney, liver, muscle, fat, and plasma. Using linear regression and mixed-effects models, we identified two SGLT2i-specific metabolites, X-12465 and 3-hydroxybutyric acid (3HBA), a ketone body, across all examined tissues...
March 17, 2024: International Journal of Biological Macromolecules